Allergen immunotherapy: A practice parameter third update

Linda Cox; Harold Nelson; Richard Lockey; Christopher Calabria; Thomas Chacko; Ira Finegold; Michael Nelson; Richard Weber; David I. Bernstein; Joann Blessing-Moore; David A. Khan; David M. Lang; Richard A. Nicklas; John Oppenheimer; Jay M. Portnoy; Christopher Randolph; Diane E. Schuller; Sheldon L. Spector; Stephen Tilles; Dana Wallace; Don Aaronson; Desiree Larenas-Linnemann; Bryan Leatherman; Sandra Y. Lin; Wesley Burkes; David Golden; Theodore M. Freeman; Derek Constable; Robert Esch; Larry Garner; Richard Lankow; Greg Plunkett; Ronald Rabin; Paul Greenberger; Bryan Martin

doi:10.1016/j.jaci.2010.09.034

Allergen immunotherapy: A practice parameter third update

Linda Cox^*, Harold Nelson, Richard Lockey, Christopher Calabria, Thomas Chacko, Ira Finegold, Michael Nelson, Richard Weber, David I. Bernstein, Joann Blessing-Moore, David A. Khan, David M. Lang, Richard A. Nicklas, John Oppenheimer, Jay M. Portnoy, Christopher Randolph, Diane E. Schuller, Sheldon L. Spector, Stephen Tilles, Dana WallaceDon Aaronson, Desiree Larenas-Linnemann, Bryan Leatherman, Sandra Y. Lin, Wesley Burkes, David Golden, Theodore M. Freeman, Derek Constable, Robert Esch, Larry Garner, Richard Lankow, Greg Plunkett, Ronald Rabin, Paul Greenberger, Bryan Martin

^*Corresponding author for this work

Medicine, Allergy Division

Research output: Contribution to journal › Article › peer-review

918 Scopus citations

Original language	English (US)
Pages (from-to)	S1-S55
Journal	Journal of Allergy and Clinical Immunology
Volume	127
Issue number	1 SUPPL.
DOIs	https://doi.org/10.1016/j.jaci.2010.09.034
State	Published - Jan 2011

Keywords

Allergy immunotherapy
Hymenoptera
allergic rhinitis
anaphylaxis
angiotensin-converting enzyme inhibitor
asthma
atopic dermatitis
epicutaneous immunotherapy
epinephrine
intralymphatic immunotherapy
nasal immunotherapy
subcutaneous immunotherapy
sublingual immunotherapy
β-blockers

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2010.09.034

Cite this

Cox, L., Nelson, H., Lockey, R., Calabria, C., Chacko, T., Finegold, I., Nelson, M., Weber, R., Bernstein, D. I., Blessing-Moore, J., Khan, D. A., Lang, D. M., Nicklas, R. A., Oppenheimer, J., Portnoy, J. M., Randolph, C., Schuller, D. E., Spector, S. L., Tilles, S., ... Martin, B. (2011). Allergen immunotherapy: A practice parameter third update. Journal of Allergy and Clinical Immunology, 127(1 SUPPL.), S1-S55. https://doi.org/10.1016/j.jaci.2010.09.034

@article{71b1f65a12e8426eb5155682261eca7a,

title = "Allergen immunotherapy: A practice parameter third update",

keywords = "Allergy immunotherapy, Hymenoptera, allergic rhinitis, anaphylaxis, angiotensin-converting enzyme inhibitor, asthma, atopic dermatitis, epicutaneous immunotherapy, epinephrine, intralymphatic immunotherapy, nasal immunotherapy, subcutaneous immunotherapy, sublingual immunotherapy, β-blockers",

author = "Linda Cox and Harold Nelson and Richard Lockey and Christopher Calabria and Thomas Chacko and Ira Finegold and Michael Nelson and Richard Weber and Bernstein, {David I.} and Joann Blessing-Moore and Khan, {David A.} and Lang, {David M.} and Nicklas, {Richard A.} and John Oppenheimer and Portnoy, {Jay M.} and Christopher Randolph and Schuller, {Diane E.} and Spector, {Sheldon L.} and Stephen Tilles and Dana Wallace and Don Aaronson and Desiree Larenas-Linnemann and Bryan Leatherman and Lin, {Sandra Y.} and Wesley Burkes and David Golden and Freeman, {Theodore M.} and Derek Constable and Robert Esch and Larry Garner and Richard Lankow and Greg Plunkett and Ronald Rabin and Paul Greenberger and Bryan Martin",

note = "Funding Information: Disclosure of potential conflict of interest: L. Cox is a consultant for Genentech/Novartis, Hollister-Stier, and Stallergenes; is a speaker for Novartis; has received research support from Stallergenes ; is on the Board of Directors for the American Board of Allergy and Immunology; and is on the US Food and Drug Administration (FDA){\textquoteright}s Allergenic Product Advisory Committee. H. Nelson is a consultant for Merck and Planet Biopharmaceuticals, is a Data and Safety Monitoring Board member of DBV Technologies, and has received research support from ALK-Abell{\'o} . M. Nelson has received research support from the Department of Defense , is a speaker for the American College of Allergy, Asthma & Immunology (ACAAI), and is a member of the FDA{\textquoteright}s Advisory Committee on Allergic Products. R. Weber is on the speakers{\textquoteright} bureau for AstraZeneca and Genentech, has received research support from Novartis and GlaxoSmithKline , and is Committee Chair of the ACAAI. D. I. Bernstein is a consultant and on the advisory board for ALK America, is on the advisory board for Merck, and has received research support from Merck and Schering-Plough. J. Blessing-Moore is a speaker for Merck-Schering/AstraZeneca, Novartis, TEVA, and Meda Alcon and has received research support from Meda . D. A. Khan is a speaker for AstraZeneca and Merck, has received research support from the Vanberg Family Foundation and the Sellars Family Foundation , is Conjoint Board Review Chair for the ACAAI, and is a past president of the Texas Allergy, Asthma and Immunology Society. D. M. Lang is a speaker and consultant for GlaxoSmithKline; is a speaker for AstraZeneca, Merck, TEVA, Sanofi-Aventis, and Genentech/Novartis; and has received research support from Genentech/Novartis . R. A. Nicklas is a fellow for the ACAAI. J. Oppenheimer is a consultant and has provided lectures for AstraZeneca, Merck, and GlaxoSmithKline; and has received research support from AstraZeneca, Merck, GlaxoSmithKline, and Genentech . J. M. Portnoy is a speaker for Phadia, Merck, and CSL Behring; has received research support from the US Department of Housing and Urban Development ; and is a board member of the ACAAI board of regents. S. L. Spector has received research support from Genentech, GlaxoSmithKline, Schering-Plough, Aventis, Novartis, Pharmaxis, Boehringer Ingelheim, AstraZeneca, Johnson & Johnson, Xyzal, Alcon, Centocor, Sepracor, UCB, Amgen, Capnia, and IVAX . S. Tilles is a speaker for Alcon; is on the advisory board for ALK, Ista, Merck, and Stallergenes; has received research support from Alcon, Amgen, Amphastar, Astellas, Boehringer Ingelheim, Ception, Genentech, Icagen, MAP Pharma, MEDA, Merck, Novartis, Roxane, and Sepracor ; is Associate Editor of Allergy Watch and Annals of Allergy; and is a task force member for the Joint Task Force for Practice Parameters. D. Wallace is a speaker and advisor for Alcon, is a speaker for Merck and Sanofi-Aventis, and is President-Elect of the ACAAI. The rest of the authors have declared that they have no conflict of interest. ",

year = "2011",

month = jan,

doi = "10.1016/j.jaci.2010.09.034",

language = "English (US)",

volume = "127",

pages = "S1--S55",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "1 SUPPL.",

}

Cox, L, Nelson, H, Lockey, R, Calabria, C, Chacko, T, Finegold, I, Nelson, M, Weber, R, Bernstein, DI, Blessing-Moore, J, Khan, DA, Lang, DM, Nicklas, RA, Oppenheimer, J, Portnoy, JM, Randolph, C, Schuller, DE, Spector, SL, Tilles, S, Wallace, D, Aaronson, D, Larenas-Linnemann, D, Leatherman, B, Lin, SY, Burkes, W, Golden, D, Freeman, TM, Constable, D, Esch, R, Garner, L, Lankow, R, Plunkett, G, Rabin, R, Greenberger, P & Martin, B 2011, 'Allergen immunotherapy: A practice parameter third update', Journal of Allergy and Clinical Immunology, vol. 127, no. 1 SUPPL., pp. S1-S55. https://doi.org/10.1016/j.jaci.2010.09.034

TY - JOUR

T1 - Allergen immunotherapy

T2 - A practice parameter third update

AU - Cox, Linda

AU - Nelson, Harold

AU - Lockey, Richard

AU - Calabria, Christopher

AU - Chacko, Thomas

AU - Finegold, Ira

AU - Nelson, Michael

AU - Weber, Richard

AU - Bernstein, David I.

AU - Blessing-Moore, Joann

AU - Khan, David A.

AU - Lang, David M.

AU - Nicklas, Richard A.

AU - Oppenheimer, John

AU - Portnoy, Jay M.

AU - Randolph, Christopher

AU - Schuller, Diane E.

AU - Spector, Sheldon L.

AU - Tilles, Stephen

AU - Wallace, Dana

AU - Aaronson, Don

AU - Larenas-Linnemann, Desiree

AU - Leatherman, Bryan

AU - Lin, Sandra Y.

AU - Burkes, Wesley

AU - Golden, David

AU - Freeman, Theodore M.

AU - Constable, Derek

AU - Esch, Robert

AU - Garner, Larry

AU - Lankow, Richard

AU - Plunkett, Greg

AU - Rabin, Ronald

AU - Greenberger, Paul

AU - Martin, Bryan

N1 - Funding Information: Disclosure of potential conflict of interest: L. Cox is a consultant for Genentech/Novartis, Hollister-Stier, and Stallergenes; is a speaker for Novartis; has received research support from Stallergenes ; is on the Board of Directors for the American Board of Allergy and Immunology; and is on the US Food and Drug Administration (FDA)’s Allergenic Product Advisory Committee. H. Nelson is a consultant for Merck and Planet Biopharmaceuticals, is a Data and Safety Monitoring Board member of DBV Technologies, and has received research support from ALK-Abelló . M. Nelson has received research support from the Department of Defense , is a speaker for the American College of Allergy, Asthma & Immunology (ACAAI), and is a member of the FDA’s Advisory Committee on Allergic Products. R. Weber is on the speakers’ bureau for AstraZeneca and Genentech, has received research support from Novartis and GlaxoSmithKline , and is Committee Chair of the ACAAI. D. I. Bernstein is a consultant and on the advisory board for ALK America, is on the advisory board for Merck, and has received research support from Merck and Schering-Plough. J. Blessing-Moore is a speaker for Merck-Schering/AstraZeneca, Novartis, TEVA, and Meda Alcon and has received research support from Meda . D. A. Khan is a speaker for AstraZeneca and Merck, has received research support from the Vanberg Family Foundation and the Sellars Family Foundation , is Conjoint Board Review Chair for the ACAAI, and is a past president of the Texas Allergy, Asthma and Immunology Society. D. M. Lang is a speaker and consultant for GlaxoSmithKline; is a speaker for AstraZeneca, Merck, TEVA, Sanofi-Aventis, and Genentech/Novartis; and has received research support from Genentech/Novartis . R. A. Nicklas is a fellow for the ACAAI. J. Oppenheimer is a consultant and has provided lectures for AstraZeneca, Merck, and GlaxoSmithKline; and has received research support from AstraZeneca, Merck, GlaxoSmithKline, and Genentech . J. M. Portnoy is a speaker for Phadia, Merck, and CSL Behring; has received research support from the US Department of Housing and Urban Development ; and is a board member of the ACAAI board of regents. S. L. Spector has received research support from Genentech, GlaxoSmithKline, Schering-Plough, Aventis, Novartis, Pharmaxis, Boehringer Ingelheim, AstraZeneca, Johnson & Johnson, Xyzal, Alcon, Centocor, Sepracor, UCB, Amgen, Capnia, and IVAX . S. Tilles is a speaker for Alcon; is on the advisory board for ALK, Ista, Merck, and Stallergenes; has received research support from Alcon, Amgen, Amphastar, Astellas, Boehringer Ingelheim, Ception, Genentech, Icagen, MAP Pharma, MEDA, Merck, Novartis, Roxane, and Sepracor ; is Associate Editor of Allergy Watch and Annals of Allergy; and is a task force member for the Joint Task Force for Practice Parameters. D. Wallace is a speaker and advisor for Alcon, is a speaker for Merck and Sanofi-Aventis, and is President-Elect of the ACAAI. The rest of the authors have declared that they have no conflict of interest.

PY - 2011/1

Y1 - 2011/1

KW - Allergy immunotherapy

KW - Hymenoptera

KW - allergic rhinitis

KW - anaphylaxis

KW - angiotensin-converting enzyme inhibitor

KW - asthma

KW - atopic dermatitis

KW - epicutaneous immunotherapy

KW - epinephrine

KW - intralymphatic immunotherapy

KW - nasal immunotherapy

KW - subcutaneous immunotherapy

KW - sublingual immunotherapy

KW - β-blockers

UR - http://www.scopus.com/inward/record.url?scp=78650918994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650918994&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2010.09.034

DO - 10.1016/j.jaci.2010.09.034

M3 - Article

C2 - 21122901

AN - SCOPUS:78650918994

SN - 0091-6749

VL - 127

SP - S1-S55

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 1 SUPPL.

ER -

Allergen immunotherapy: A practice parameter third update

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this